New Delhi, Aug. 14 – Air India has officially initiated a comprehensive drug screening program for its entire pilot workforce following a concerning mid-air incident. This proactive measure mandates that all pilots within the airline and its subsidiary, Air India Express, undergo testing for prohibited substances and medications. The decision comes after a captain involved in an August 4 flight from Phuket to New Delhi reportedly tested positive for marijuana. The sudden altitude loss during that flight resulted in injuries to several passengers, prompting rigorous investigations and a heightened focus on flight crew fitness.
The airline’s internal memo confirms that this initiative surpasses existing regulatory requirements, which previously mandated only random testing for at least ten percent of flight crews annually. By implementing universal screening, Air India aims to reinforce its commitment to aviation safety and restore trust among passengers and stakeholders. The airline emphasizes that maintaining the highest standards of professionalism is its most critical asset as it navigates this period of increased scrutiny.
Testing protocols will be strategically integrated into pilot schedules, occurring during training sessions at the airline’s Gurugram academy, at flight briefing centers, and at designated home bases. This logistical approach ensures that the expanded oversight is thorough, consistent, and systematically applied across the entire group.
This aggressive expansion of drug testing highlights a broader push to ensure strict adherence to aviation regulations in India. By proactively screening all pilots for psychoactive substances, the airline seeks to prevent potential lapses in safety. As the investigation into the Phuket-Delhi flight continues, the aviation industry remains vigilant regarding the importance of pilot health and the severe consequences of substance use in the cockpit.